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Abstract
Purpose: We investigated the usefulness of [99mTc]duramycin for monitoring early response to
cancer therapy in mice, with an eye towards clinical translation.
Procedures: [99mTc]Duramycin was injected in healthy CD1−/− mice to estimate human
[99mTc]duramycin radiation dose. [99mTc]Duramycin single-photon emission computed tomog-
raphy (SPECT) imaging of apoptosis was evaluated in a mouse model of colorectal cancer
treated with irinotecan and validated ex vivo using autoradiography, cleaved caspase-3, and
TdT-mediated dUTP nick-end labeling (TUNEL) histology of the tumors.
Results: The mean effective dose was estimated to be 3.74×10−3±3.43×10−4 mSv/MBq for
non-purified and 3.19×10−3±2.16×10−4 mSv/MBq for purified [99mTc]duramycin.
[99mTc]Duramycin uptake in vivo following therapy increased significantly in apoptotic
irinotecan-treated tumors (p=0.008). Radioactivity in the tumors positively correlated with
cleaved caspase-3 (r=0.85, pG0.001) and TUNEL (r=0.92, pG0.001) staining.
Conclusion: [99mTc]Duramycin can be used to detect early chemotherapy-induced tumor cell
death, and thus, may be a prospective candidate for clinical SPECT imaging of tumor response
to therapy.
Key words: 99mTc, Duramycin, Preclinical dosimetry, Small-animal SPECT imaging, Chemo-
therapy, Apoptosis
Introduction
Monitoring early tumor response to therapy is a majorpriority in oncology. Currently, the most commonly
used methodology to evaluate the effectiveness of a given
therapeutic regimen is still based on morphological and
volumetric criteria (e.g., RECIST) [1]. However, these
methods are not sensitive enough to assess early effects of
therapy. Molecular imaging can offer clinicians a direct and
specific tool to follow-up response to cancer therapy,
allowing changing therapy early on in non-responding
patients, avoiding unnecessary toxicity and increasing
treatment effectiveness.
Apoptosis is a highly regulated process that plays a vital
role in the pathogenesis of cancer [2]. The ability to evade
apoptosis is an established hallmark of cancer [3] and most
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cancer therapies such as chemotherapy, radiotherapy, or
targeted therapies have a pro-apoptotic [4] but also a necrotic
effect [5, 6]. Early in the apoptotic cascade, there is a
redistribution of cell membrane aminophospholipids, such
as phosphatidylethanolamine (PE) and phosphatidylserine
(PS), normally present in the inner leaflet of the cell
membrane. PE, the second most abundant phospholipid in
the membrane bilayer (15–25 %), becomes early accessible
during apoptosis due to exposure to the outer leaflet of the
cell membrane and during necrosis due to disruption of the
cell membrane [7]. Since anti-cancer therapy can result in
necrosis and late apoptotic cells can also become necrotic,
imaging cell death in all its forms is important from a clinical
point of view. To date, several positron emission tomogra-
phy (PET) and single-photon emission computed tomogra-
phy (SPECT) cell death imaging agents have already been
explored, including radiolabeled annexin-V [8–10], C2A
domain of synaptotagmin-I [11], Zn2+-DPA [12], and
caspase inhibitors [13], but they have all failed to reach
clinical usefulness. The most studied one to date is PS-
targeting [99mTc]annexin-V. Although this tracer has been
used in many studies as the prototypical cell death-targeting
imaging agent, it has several limitations, most notably its
slow clearance due to its large protein structure. This
radiotracer showed a high liver and kidney uptake, thus
increasing the background noise from non-targeted tissues.
PS externalization is not specific for apoptosis, occurring
also in activated macrophages, which are known to be
present in tumors after therapy [14]. Furthermore, it is
known that PS-expressing cells can be rapidly cleared by
macrophages before the radiotracer can target those cells.
These findings suggest that [99mTc]annexin-V is unspecific
and cannot be exclusively considered a cell death marker.
There currently is a need for novel, more selective, and
specific small-molecule cell death imaging agents with high
stability in vivo. Ideally, these agents should have avid target
uptake, with high selectivity for dead cells, favorable in vivo
distribution, with rapid blood clearance and low hepatic
background, and be easily integrated in the clinical practice.
In this way, PE provides a molecular biomarker for the
detection of cell death (apoptosis and necrosis) and has
become a target for radiotracer development.
Duramycin is a 19-amino acid peptide that recognizes
both apoptotic and necrotic cells by binding to PE with high
affinity (Kd∼5 nM) and specificity [15]. The low molecular
weight (MW) of duramycin (∼2 kDa) confers this tracer with
favorable pharmacokinetics and biodistribution properties
for in vivo imaging of apoptosis [16]. [99mTc]Duramycin has
been successfully used as a probe for the imaging of cell
death in animal models of cerebral [17] and myocardial [18,
19] ischemia–reperfusion, accumulating in tissue sites of
injury where there is high apoptotic activity. Additionally,
this probe was also effectively used to assess tissue damage
after whole-body irradiation [20]. A combination of high
affinity, superior in vivo performance and the use of a
radioisotope (Tc-99m) already implemented in the clinical
routine in most hospitals makes [99mTc]duramycin a notable
candidate for oncology imaging applications.
We therefore hypothesized that [99mTc]duramycin could
potentially be used to quantify treatment-induced tumor cell
death. Based on this hypothesis, we evaluated the use of
[99mTc]duramycin for imaging of chemotherapy-induced
tumor cell death in tumor-bearing mice. A kit formulation
was previously developed by Zhao and colleagues to obtain
injection-ready [99mTc]duramycin [18]. Since in preliminary
studies we found suboptimal purity of kit prepared
[99mTc]duramycin, we have first assessed the impact of
radiotracer purification on the biodistribution and dosimetry
profile. This study will be of value for the future use and
possible clinical translation of [99mTc]duramycin and for the
development of second generation kit formulations.
Materials and Methods
Radiolabeling of Duramycin
A single-step kit formulation (MTTI, USA) composed of 15 μg
hydrazinonicotinamide- (HYNIC) duramycin, 30 mg tricine,
9.5 mg trisodium triphenylphosphine-3,3′,3″-trisulfonate, and
6.25 μg SnCl2 was used for Tc-99m labeling. Approximately,
1,480 MBq [99mTc]pertechnetate in 500 μl of saline was added to
the kit and heated at 80 °C for 20 min. The radiopharmaceutical
was used without or with purification. In the last case,
[99mTc]duramycin obtained from the kit was purified after
radiolabeling using the following high-performance liquid chroma-
tography (HPLC) method. For reverse phase (RP) HPLC, a C18
column (Grace Vydac 218TP, 5 μm, 300 Å, 250×4.6 mm) was
used with a gradient elution of 25 mM NaH2PO4 pH 6.7 and
acetonitrile, a flow rate of 1 ml/min and UV/VIS (λ=215 nm,
Shimadzu, Japan) and radio-detection (NaI scintillation detector,
Raytest, Germany). After collection of the fraction containing
[99mTc]duramycin (retention time of 16 min), solvents were
evaporated under N2, and the radiopharmaceutical was
reconstituted in saline with 5 % ethanol for in vitro and in vivo
use. Radiochemical purity (RCP) was determined by analytical
HPLC using the same method used for the purification of the
radiotracer.
Dosimetry and Biodistribution Studies
Experimental procedures and protocols were performed in accor-
dance with European Directive 86/609/EEC Welfare and Treatment
of Animals and were approved by the local ethical commission
(2013-36, University of Antwerp, Belgium). Healthy immunodefi-
cient CD1−/− nude female mice (Charles River Laboratories,
Belgium), weighing 24–29 g were intravenously (i.v.) injected
with 37 MBq non-purified (n = 3) or purified (n = 6)
[99mTc]duramycin via lateral tail vein catheterization. Immediately
at injection, dynamic whole-body images were acquired during
60 min using a SPECT-X-ray computed tomography (CT) scanner
(VECTor/CT, MILabs, The Netherlands) equipped with a rat multi-
pinhole SPECT collimator. Frames were acquired at 1-min intervals
for the first 10 min, followed by 5-min acquisitions for the
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remaining 50-min period. Thereafter, 30-min static scans (six
frames of 5 min) were acquired at 4, 8, and 24 h post-radiotracer
injection (p.i.). The energy window was centered at 140 keV
photopeak with a 20 % energy window for Tc-99m. For
quantitative analysis, SPECT data were reconstructed with ordered
subset expectation maximization using 10 iterations of 16 subsets
and 1.2-mm3 voxel size. Following each μSPECT acquisition, a
whole-body high-resolution micro-computed tomography (μCT)
scan was performed to obtain anatomical information for segmen-
tation. Throughout the entire SPECT-CT scanning procedure, the
mice were kept under isoflurane anesthesia and a constant body
temperature was maintained using a heating pad.
Volumes of interest (VOIs) were manually drawn on the
μSPECT-CT images using PMOD v3.3 (PMOD Technologies,
Switzerland) to delineate the regions with distinct SPECT time-
activity pattern: heart, liver, kidney, and urinary bladder, as well as
whole-body. The average organ activity per volume was obtained
from the co-registered μSPECT images and the non-decay
corrected time activity curves (TACs) were extracted for each
target organ. In order to relate the scanner units (counts/pixel) to
radioactivity concentration (kilobecquerel per cubic centimeter), a
scanner calibration factor was estimated by scanning a syringe with
a known concentration of Tc-99m. TACs for each organ, as well as
the TACs representing the activity in the remainder of the body,
were fitted by a single exponential decaying function, which was
then integrated to obtain the total number of disintegrations
(residence time) within these regions. In order to predict human
dosimetry using animal data, interspecies extrapolation is neces-
sary. Thus, the residence times (R) were scaled to human values















The human organ and body weight values from the standard adult
male phantom taken into account are implemented in the internal
dosimetry software (OLINDA/EXM v1.1) [22] and are assumed to be
constant across individuals. The body weight and organ masses for the
individual mice were obtained post-mortem. For the bladder model,
the fraction leaving the body via the urinary excretion system (f) and
the biological half-life of the excretion (t1/2) were estimated by fitting a
first-order linear system to the sum of activity in the bladder and the
activity that had been excreted (calculated as total injected activity
minus total body activity):




Projected human absorbed doses to various organs and the
effective doses (ED) were then computed using the aforementioned
dosimetry software (weighting factors from International Commis-
sion on Radiological Protection 60) [23], with the human residence
times as input, using the standard adult male model and the
dynamic voiding bladder model [24] (2-h voiding interval).
After the last static scan (24 h p.i.) blood was collected through
cardiac puncture, and the mice were euthanized by cervical
dislocation for ex vivo biodistribution. The organs and tissues were
harvested, weighed and the radioactivity in the samples was
measured in an automatic gamma- (γ) counter (Wizard2 2480,
Perkin Elmer, USA) using an energy window of 140±19 keV.
Uptake levels of [99mTc]duramycin are presented as percentage
injected dose per gram (%I.D./g).
In Vitro Tumor Cell Uptake of [99mTc]Duramycin
A semi-adherent human colorectal adenocarcinoma cell line
(COLO205; firefly luciferase gene 2 transfected; Perkin Elmer,
Belgium), was grown as previously described [9]. The cells were
maintained in RPMI 1640 medium supplemented with 2 mML-
glutamine, 1 mM sodium pyruvate, 10 % fetal bovine serum and
100 U/ml penicillin plus 100 mg/ml streptomycin (Life Technol-
ogies, Belgium) at 37 ° C in a humidified atmosphere containing
5 % CO2. The cells were kept in exponential phase by routine
passage every 2 to 3 days (split ratio: 1/2–1/6), and then plated into
six-well plates (Thermo Scientific, USA) at a density of 5.3×103
cells/cm2. Two days after, COLO205 cells were treated with three
increasing concentrations of irinotecan (0.43, 4.3, and 43 μM;
Teva, Belgium) or left untreated (control group) for 40 h (n=6 per
group). [99mTc]duramycin (0.19 MBq; purified) was then incubated
in each well at 37 ° C in a humidified atmosphere of 5 % CO2 for
30 min. Cells were washed and after centrifugation at 150×g for
5 min the supernatant was discarded. Finally, cells were resus-
pended and counted using Muse Count & Viability Assay
(Millipore, USA). After subsequent centrifugation, the cell-bound
radioactivity in the pellet was determined by automatic γ-counting.
Radioactivity (CPM) per 103 cells was determined and uptake
expressed as a percentage of untreated cells. The levels of cell death
(apoptosis and necrosis) were assessed by using Muse Annexin V
& Dead Cell Assay (Millipore, USA), and Muse Caspase 3/7 Assay
Kit (Millipore, USA).
In Vivo Tumor Uptake of [99mTc]Duramycin
Female nude mice (n=6) were subcutaneously injected with
luciferase-transfected COLO205 cells (2×106 in 100 μl) in both
hind legs, as previously described [8]. Tumor volume was
monitored using a digital caliper before drug administration
(baseline values) and at consecutive days after the start of therapy.
Volumes were calculated according to the formula: (length×
width2)/2. Two weeks after inoculation, when the tumors reached
a volume of approximately 400 mm3 (n=12 tumors), mice were
treated using chemotherapy or vehicle. Irinotecan was administered
by intra-peritoneal (i.p.) injection (80 mg/kg) three times in 1 week
every other day (n=3). Vehicle-treated (0.9 % NaCl), tumor-
bearing mice were used as controls (n=3). Relative tumor volume
was calculated as follows: RTV=(mean tumor volume during
treatment)/(mean tumor volume before treatment start). Percentage
of tumor growth inhibition was calculated as follows: %TGI=[1
−(Mean RTV of irinotecan group/Mean RTV of vehicle group)×
100]. Tumor growth was also monitored using whole body
bioluminescence imaging (BLI) before and after the treatment.
Twenty-four hours after the last injection of irinotecan or vehicle
COLO205-bearing mice were i.v. injected with purified
[99mTc]duramycin (37 MBq). Four hours p.i., mice were positioned
in the scanner and static SPECT images were acquired during
30 min (six frames of 5 min) followed by a μCT scan as described
above. VOIs were manually drawn around all the tumor dimensions
on the obtained CT images using PMOD software. After
delineation, tracer uptake was quantified as: [Total radioactivity in
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the tumor at the time of scan (in kilobecquerel)/Total radioactivity
injected (in kilobecquerel)] and normalized to tumor weight (in
gram) and body weight (in kilogram) (percentage injected dose per
gram per kilogram). Standardized uptake values (SUVs) were used
to evaluate [99mTc]duramycin uptake by bone marrow. Three-
dimensional regions of interest were drawn on the CT images to
delineate the bone marrow in the lumbar vertebrae and the sacrum.
SUVs were calculated as follows: SUV=[Measured radioactivity
concentration (in kilobecquerel per cubic centimeter)]/[Decay-
corrected amount of injected activity (in kilobecquerel)/Body
weight (in kilogram)×1,000]. Mice were sacrificed for ex vivo
biodistribution and the radioactivity in the tumors and organs was
determined by γ-counting.
Ex Vivo Validation
Immediately after γ-counting, tumors (n=6/treatment) were embed-
ded and snap-frozen in tissue-Tek (OCT compound, VWR, USA).
For autoradiography studies, frozen tissue sections (100 μm) were
sliced, dried at 37 ° C for 1 h and exposed to phosphor screen plates
(Fujifilm, USA) overnight. Plates were imaged in a Phosphor
Imager system (FLA7000, GE Healthcare, USA). After undergoing
radioactive decay, hematoxylin and eosin staining (H&E) was
performed in these tumor sections. In parallel, adjacent frozen
tumor sections (10 μm) were used for histological analysis of
apoptosis, by immunostaining of cleaved caspase-3 (CC3, Cell
Signaling, USA) and TdT-mediated dUTP nick-end labeling
(TUNEL) assay (Promega, USA), according to manufacturer’s
instructions. For CC3 staining, the appropriate HRP-conjugated
secondary antibody (DAKO EnVision, Belgium) was used. The
nuclei of the tissue sections were counterstained using Mayer’s
hematoxylin (Sigma-Aldrich, USA). Apoptosis was quantified by
manually counting CC3- and TUNEL-positive cells in three non-
sequential whole tumor sections (n=6/treatment). Sections were
scored by two independent operators in a masked way using an
upright microscope at ×400 magnification (Olympus CX31, USA).
Extensive necrotic areas were excluded from the analysis.
Statistical Analysis
Results are expressed as mean±SEM, unless otherwise indicated.
Statistical differences between two data sets were analyzed by the
unpaired Student’s t test (two tailed) with Welch’s correction. One-
way ANOVA or two-way repeated-measures ANOVA tests were
used for multiple comparisons between groups, followed by
Bonferroni correction. Pearson correlation r was computed to
calculate the correlations between uptake of [99mTc]duramycin and
CC3- and TUNEL-positive cells in the tumors (Prism v6.01,




Duramycin was labeled with Tc-99m using the HYNIC-tricine-
phosphine chelation core. The RCP was 84±6 % (n=11), as
assessed by RP-HPLC analysis. As shown in Fig. 1a, after
radiolabeling, low amounts of polar impurities could be
detected in the [99mTc]duramycin formulation. However, upon
HPLC purification, the RCP increased to 99±2 % (n=7;
Fig. 1b).
Fig. 1 Typical radio-HPLC chromatograms of [99mTc]duramycin a before and b after purification. CPS: counts per second.
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Dosimetry and Biodistribution Studies
We then explored the influence of purification on the
biodistribution profile of [99mTc]duramycin. [99mTc]duramycin
cleared rapidly via the kidneys resulting in general low
background from 4 h until 24 h p.i. (Fig. 2a, b). Four hours
p.i., the purified radiotracer demonstrated faster blood clear-
ance (0.62±0.27 vs. 1.46±0.46%I.D./cc for the non-purified
radiotracer; p=0.025) and renal excretion (6.82±0.41 vs. 8.58
±0.15%I.D./cc for the non-purified radiotracer; p=0.010).
Furthermore, the non-purified radiotracer showed higher initial
accumulation in the liver that remained elevated until 24 h p.i.
as evidenced by ex vivo biodistribution (Fig. 2c) (14.69±1.09
vs. 1.66±0.29%I.D./g for the purified radiotracer; pG0.001).
Additionally, non-purified radiotracer showed higher splenic
and renal uptake (4.80±0.46; p=0.006 and 14.21±4.39%I.D./
g; pG0.001, respectively) when compared with the purified
tracer (2.04±0.35 and 6.98±0.42%I.D./g, respectively)
(Fig. 2c). Therefore, this intense uptake in non-targeted organs
makes it difficult to interpret the activity in surrounding tissues,
resulting in images with lower signal-to-background ratio
(Fig. 2b). HPLC purification of [99mTc]duramycin resulted in
images with lower background levels, enabling vivid tumor
imaging. No significant differences in radiotracer uptake could
be detected in the remaining organs analyzed 24 h p.i. (Fig. 2c).
The highest level of disintegrations per organ occurred
in the liver for the non-purified and in the urinary bladder
for the purified radiotracer with residence times of 1.02 h
and 6.43×10−1 h, respectively (Table 1). Table 2 summa-
rizes the mean organ absorbed dose estimates for
[99mTc]duramycin. The mean ED were estimated to be
3.74×10−3±3.43×10−4 and 3.19×10−3±2.16×10−4 mSv/
MBq for the non- and purified [99mTc]duramycin, respec-
tively. Interestingly, for the non-purified radiotracer the
highest absorbed dose was received by the urinary bladder
wall (1.66×10−2±4.55×10−3 mGy/MBq), followed by the
liver (1.27×10−2±5.97×10−3 mGy/MBq). In the case of
purified [99mTc]duramycin, the highest absorbed doses
were received by the urinary bladder wall (2.70×10−2±
3.05×10−3 mGy/MBq) and the uterus (4.57×10−3±3.42×
10−4 mGy/MBq).
The data obtained indicate less optimal dosimetry and
imaging properties for non-purified [99mTc]duramycin.
Therefore, Tc-99m labeled-duramycin was only used after
HPLC purification in the following.
In Vitro Uptake
As shown in Fig. 3a, treatment with 4.3 and 43 μM of
chemotherapeutic agent irinotecan significantly increased the
binding of the radiotracer to 301.50±43.15 % (p=0.003) and
479.90±49.44 % (pG0.001), respectively, when compared
to untreated cells (100.00±19.09 %). Importantly, this
marked binding of [99mTc]duramycin by the cells was
associated with an increase in apoptosis levels as a result
of irinotecan treatment, as demonstrated by the good
correlation with the binding of annexin-V and effector
caspase activation. Moreover, cell treatment did not result
in an increased level of cell necrosis (Fig. 3b, c).
In Vivo Uptake
COLO205 cells were inoculated in both hind limbs of nude
mice in order to reduce the number of animals to be used in
this study. Importantly, baseline tumor growth (before
treatment) was comparable in both flanks for all the mice
(data not shown). The tumor growth curves for each
treatment are presented in Fig. 4a. While in vehicle-treated
animals the tumors exponentially increased in volume until
day 5 (1.98±0.23), in mice treated with irinotecan, tumor
growth was significantly inhibited at day 5 (1.30±0.14; p=
0.008), which corresponded to a tumor growth inhibition of
34.4±6.9 %. Also, after treatment the bioluminescent signal
Fig. 2 Representative μSPECT-CT images up to 24 h post injection of a non-purified and b purified 37 MBq [99mTc]duramycin
in healthy mice. c Ex vivo biodistribution (%I.D./g±SEM) at 24 h p.i. Normalized images were scaled according to the percent
injected dose (tissue uptake[kBq/cc]/injected dose[kBq]*100). Images are presented in the sagittal orientation. **pG0.01,
***pG0.001, significantly different from non-purified [99mTc]duramycin.
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in the tumors of irinotecan-treated mice was significantly
diminished (0.75±0.28; p=0.001) when comparing with the
control (Fig. 4b). Although treatment with irinotecan is normally
associated with myelosuppression, at the time point used for
imaging no significant differences were found in
[99mTc]duramycin bone marrow uptake between irinotecan- and
vehicle-treated mice (SUV, 0.12±0.02 and 0.11±0.01, respec-
tively; p=0.913). No overall toxicity with respect to body weight
loss was observed at the dose of 80 mg/kg irinotecan (data not
shown). Based on Fig. 2, we determined that 4 h post
[99mTc]duramycin injection is the optimal time point for imaging,
allowing enough blood clearance and low background for tumor
imaging. Accordingly, Fig. 5 shows μSPECT-CT images 4 h p.i.
of tumor-bearing mice 24 h after the last vehicle (Fig. 5a) or
irinotecan (Fig. 5b) treatment. The mean tumor uptake value of
[99mTc]duramycin was significantly higher in the irinotecan-
treated group (148.50±25.42%I.D./g/kg; p=0.008), compared to
the vehicle-treated group (40.58±2.81%I.D./g/kg). Similarly
tumor-to-muscle and tumor-to-blood uptake ratios for the
irinotecan-treated mice were 2-fold (pG0.001) and 6-fold higher
(pG0.001) over the vehicle–treated mice, respectively. No
correlation was found between tumor size and radiotracer uptake
in the tumors (Pearson r=−0.29; p=0.36).
Ex Vivo Validation
The uptake of [99mTc]duramycin in the irinotecan-treated
tumors (1.65±0.13%I.D./g) was significantly higher than in
control tumors (0.74±0.04%I.D./g; pG0.001), as assessed by
γ-counting. The treatment with irinotecan did not induce
differences in radiotracer uptake in the remaining organs
when comparing with the control (data not shown).
Table 1. Mean human residence times (in hour) estimates for non-purified and purified [99mTc]duramycin
Non-purified (n=3) (f=0.519; t1/2=2.950 h) Purified (n=6) (f=0.697; t1/2=2.151 h)
Target organs Mean SD Mean SD
Heart contents 2.44×10−2 7.52×10−3 2.70×10−2 6.15×10−3
Kidneys 1.30×10−1 5.73×10−2 5.49×10−2 1.30×10−2
Liver 1.02 5.09×10−1 7.50×10−2 2.03×10−2
Urinary bladder contents 3.69×10−1 1.22×10−1 6.43×10−1 7.75×10−2
Remaining body 3.41 6.23×10−1 2.54 2.13×10−1
f mean fraction leaving the body via the urinary excretion system, t1/2 mean biological half-life of the excretion
Highest mean human residence times are presented in bold
Table 2. Mean human organ absorbed dose (milligray per megabecquerel) for different organs and effective dose (millisievert per megabecquerel) estimates
for non- and purified [99mTc]duramycin
Non-purified (n=3) Purified (n=6)
Organs Mean SD Mean SD
Adrenals 3.90×10−3 1.13×10−3 1.74×10−3 1.23×10−4
Brain 1.54×10−3 2.86×10−4 1.14×10−3 9.39×10−4
Breasts 1.51×10−3 3.04×10−4 9.59×10−4 7.44×10−5
Gallbladder wall 5.38×10−3 1.84×10−3 1.84×10−3 1.25×10−4
LLI wall 3.01×10−3 2.26×10−4 2.97×10−3 1.86×10−4
Small intestine 3.01×10−3 4.53×10−4 2.22×10−3 1.34×10−4
Stomach wall 2.63×10−3 5.57×10−4 1.59×10−3 1.16×10−4
ULI wall 3.10×10−3 5.71×10−4 2.03×10−3 1.26×10−4
Heart wall 3.12×10−3 7.80×10−4 1.91×10−3 1.63×10−4
Kidneys 8.45×10−3 3.27×10−3 3.63×10−3 6.31×10−4
Liver 1.27×10−2 5.97×10−3 1.64×10−3 2.39×10−4
Lungs 2.52×10−3 6.00×10−4 1.36×10−3 1.03×10−4
Muscle 2.12×10−3 3.35×10−4 1.55×10−3 9.64×10−5
Ovaries 3.15×10−3 2.59×10−4 2.96×10−3 1.78×10−4
Pancreas 3.79×10−3 1.02×10−3 1.82×10−3 1.30×10−4
Red marrow 2.16×10−3 3.76×10−4 1.48×10−3 9.73×10−5
Osteogenic cells 5.51×10−3 9.74×10−4 3.92×10−3 2.91×10−4
Skin 1.34×10−3 2.33×10−4 9.56×10−4 6.88×10−5
Spleen 2.48×10−3 4.93×10−4 1.59×10−3 1.17×10−4
Testes 2.11×10−3 1.86×10−4 2.07×10−3 1.28×10−4
Thymus 2.03×10−3 3.93×10−4 1.39×10−3 1.07×10−4
Thyroid 1.87×10−3 3.42×10−4 1.38×10−3 1.13×10−4
Urinary bladder wall 1.66×10−2 4.55×10−3 2.70×10−2 3.05×10−3
Uterus 4.05×10−3 2.43×10−4 4.57×10−3 3.42×10−4
Total body 2.52×10−3 4.76×10−4 1.62×10−3 1.01×10−4
Effective dose 3.74×10−3 3.43×10−4 3.19×10−3 2.16×10−4
Highest mean human organ absorbed doses and effective dose are presented in bold
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Figure 6 shows representative autoradiographs and H&E-,
CC3-, and TUNEL-stained sections of tumors from mice
treated with vehicle and irinotecan. Autoradiographs show a
heterogeneous uptake of [99mTc]duramycin in the tumors,
which was higher in tumors treated with irinotecan (Fig. 6a).
Compared with tumors from vehicle-treated mice, treatment
with irinotecan caused cell shrinkage and condensed cytoplasm
(Fig. 6b), formation of apoptotic bodies, increase in the number
of CC3-positive cells (Fig. 6c; arrows) (9.5±1.1 vs. 1.8±0.4 in
the control; pG0.001), and DNA fragmentation, as assessed by
an increase in the number of TUNEL-positive cells (Fig. 6d;
arrows) (10.5±1.6 vs. 3.5±0.7 in the control; p=0.006). Most
importantly, this extensive apoptotic response was highly
correlated with [99mTc]duramycin uptake in the tumors (CC3,
r=0.85 and pG0.001, and TUNEL, r=0.92 and pG0.001). The
distribution of the apoptotic cells in the tumors matched the
distribution of [99mTc]duramycin radioactivity. In control
tumors, cold spots colocalized with low number of apoptotic
cells, whereas in treated tumors high number of apoptotic cells
corresponded to hot spots with high radioactivity (Fig. 6;
boxes).
Discussion
A kit formulation was developed by Zhao and Li to allow a
rapid, consistent, and reproducible radiolabeling of
duramycin with Tc-99m with high RCP and specific activity
[18]. Radiopharmaceutical kits should provide a simplified
labeling procedure, yielding high-purity compounds without
the need to remove radiochemical impurities. In this study
however, we found that the single-step kit formulation
resulted in [99mTc]duramycin with unsatisfactory RCP
(84 %), hence does not meet the quality specifications
desired (995 % RCP). Based on these results, we conducted
a preliminary comparative study on the impact of column
purification in animal imaging experiments. Purification of
the radiopharmaceutical will remove other radiolabeled
species and excess “unlabeled” HYNIC-duramycin that
may compete with the radiopharmaceutical in normal or
tumor tissues. Our study provides evidence that purification
of the [99mTc]duramycin has a prominent impact on the
biodistribution profile in mice. Indeed, injection of purified
[99mTc]duramycin led to rapid washout of activity from the
blood pool and fast elimination primarily via renal clearance,
as previously described in rats [16]. On the contrary, the
non-purified radiotracer showed a slower blood clearance,
high spleen uptake, and a combination of urinary and
hepatobiliary clearance. A possible present impurity is Tc-
99m tin colloid resulting from oxidation and hydrolysis of
tin during the labeling [25]. It is well described that tin
colloids result in high liver and spleen uptake [26] due to
phagocytosis by the reticuloendothelial cells in these organs.
However, since a similar biodistribution profile was obtained
using [18F]duramycin [27], colloid formation cannot exclu-
sively explain the high liver and spleen uptake for non-
purified [99mTc]duramycin. Another possible explanation for
the higher blood pool activity and liver uptake of non-
purified [99mTc]duramycin might be the competition of present
Fig. 3 a. In vitro uptake of [99mTc]duramycin in COLO205 cells after incubation with irinotecan. Detection of apoptosis by b
Annexin-V and c Caspase-3/7 assays. **pG0.01, ***pG0.001, significantly different from control.
Fig. 4 a Tumor growth curves for vehicle-treated (circles) and irinotecan-treated (squares) tumors. The arrows indicate the
days of treatment administration. b BLI signal change after tumor treatment. **pG0.05 significantly different from the vehicle at
D5*; ##pG0.01 significantly different from the vehicle.
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unlabeled HYNIC-duramycin and co-ligands with the tracer in
the excretion pathway. Also, the abundant expression of PE in
lipoproteins in the liver of mice [28] may explain the increased
liver uptake of [99mTc]duramycin. Towards the use of
[99mTc]duramycin in a mouse model of cancer, it is highly
desirable that this radiotracer clears from non-target organs,
such as liver and spleen, so that a high tumor-to-background
ratio can be achieved. Future efforts will be directed towards
optimization of the kit composition, radiolabeling conditions,
and purification methodologies (e.g., solid-phase extraction),
in order to obtain injection-ready [99mTc]duramycin sufficient-
ly amenable for clinical use.
Since the dosimetry profile of [99mTc]duramycin has not
yet been described, we extrapolated the human organ
absorbed radiation doses from calculated residence times in
mouse organs obtained by whole-body μSPECT-CT, as
useful information towards the clinical translation of
[99mTc]duramycin. Notably, for both non-purified
(0.0037 mSv/MBq) as purified (0.0032 mSv/MBq)
[99mTc]duramycin the mean ED were lower than for other
apoptosis imaging agents such as [18F]ICMT11 (0.025 mSv/
MBq) [29], [18F]CP18 (0.0056 mSv/MBq) [30] or
[99mTc]HYNIC-annexin V (0.011 mSv/MBq) [31]. More-
over, this dosimetry study showed that [99mTc]duramycin
meets the criteria for radiation exposure towards future use
of this tracer in a clinical set-up. The estimated radiation
doses are within the limits described by the European
guidelines [32] and US Food and Drug Administration
[33]. Importantly, frequent bladder voiding in a clinical
imaging scenario, would decrease the absorbed dose to the
urinary bladder wall, which was the critical organ receiving
the highest dose using the non-purified (1.66×10−2 mGy/
MBq ) a n d p u r i f i e d ( 2 . 7 0 × 1 0 − 2 mGy /MBq )
[99mTc]duramycin. Another organ receiving a relatively high
Fig. 5 Representative μSPECT-CT images 4 h p.i. of tumor-
bearing mice 24 h after the last course of treatment with a
vehicle and b 80 mg/kg irinotecan. Tumors are encircled.
Fig. 6 Histological and autoradiography analysis of tumor specimens. a Representative autoradiographic images, b
hematoxylin and eosin staining, c cleaved caspase-3 immunostaining, and d TUNEL staining for vehicle-treated (upper
panels) and irinotecan-treated (lower panels) tumors. Cells in brown were positive for caspase-3 and TUNEL stainings (arrows).
Boxes indicate the areas where zoomed images were acquired. AU: arbitrary units.
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dose using the non-purified radiotracer was the liver (1.27×
10−2 mGy/MBq), reflecting slower excretion kinetics and
higher radiotracer retention in the liver, compared to the
purified radiotracer. Taken together, these findings suggest
that HPLC-purified [99mTc]duramycin is the better candidate
for prospective human studies.
Molecular imaging of cell death has gained interest in
oncology for monitoring tumor response to cancer therapy.
Radiolabeled annexin-V was the first cell death-specific probe
to be evaluated clinically [31]. The exposure of membrane
aminophospholipids such as PS and PE in the extracellular
milieu provides surrogate markers for detecting cell death. PE
presents one of the most abundant targets in the membrane
bilayer, only preceded by phosphatidylcholine. This higher
availability of binding sites represents a clear advantage of
duramycin over PS-binding counterparts (e.g., annexin-V).
Other limitations of annexin-V include limited tumor penetra-
tion [34] and slow clearance from non-targeted tissues [10] due
to its large protein structure and high MW (31–36 kDa),
reducing signal-to-background ratios. The small (∼2 kDa)
polypeptide structure of duramycin enables better tissue
penetration and fast clearance from non-targeted organs, which
renders it a good candidate biomarker for molecular imaging of
cell death in oncology. Besides aminophospholipid targeting
tracers other molecules targeting additional hallmarks of
apoptosis have been developed. Most notably, [18F]ICMT-11
is a non-peptide isatin sulfonamide with nanomolar binding
affinity for caspase-3/7 [29]. Less attractive in this family of
molecules is the potential suboptimal metabolic stability, in
part due to hydroxylation at the isatin aromatic ring [35] and
non-specific interactions of the dicarbonyl functionality at the
cysteine binding site of the enzyme [36], which may result in
unsatisfactory PET imaging. In contrast, duramycin has unique
characteristics that confer this radiotracer a superior metabolic
stability. The four covalent intramolecular bridges and the
absence of a free peptide terminus confer this peptide a better
stability and resistance to in vivo degradation [16]. We
examined the metabolic stability of [99mTc]duramycin in
normal CD1−/− mice. According to the radio-HPLC analysis
of plasma samples, the majority of the injected
[99mTc]duramycin remains unchanged after 4 and 24 h p.i.
(see Online Resource). Recently another interesting PET
radiotracer, [18F]ML-10 has been described, targeting a
complex set of features of apoptotic cells [37]. This tracer
showed to be a promising tool for molecular imaging of
apoptosis and is currently in Phase I/II clinical studies.
Although PET radiotracers benefit from the superior sensitivity
of PET, SPECT imaging has the advantage of having lower
operational costs since it does not require an on-site cyclotron
and Tc-99m generators are installed in most hospitals, making
its use more suitable in clinical routine.
Above-mentioned factors account for [99mTc]duramyin’s
suitability for imaging of cell death. Although the cell death
imaging properties of this tracer have been previously
explored in animal models of cerebral [17] and myocardial
[18] infarction, pulmonary hyperoxia [38], and whole-body
irradiation [20], to our knowledge, imaging of treatment
response to cancer therapy using [99mTc]duramycin has not
yet been described. We therefore explored the cell death
targeting properties of [99mTc]duramycin in a mouse model
of colorectal cancer treated with the chemotherapy drug
irinotecan. This chemotherapy treatment was chosen since
campothecin–analog irinotecan is a key component of first-
and second-line clinical therapy regimens for colorectal
cancer [39], which has already shown a cytotoxic effect in
COLO205 cells [8]. SPECT imaging with [99mTc]duramycin
revealed an increased accumulation of the radiotracer in the
tumors 24 h after the last irinotecan treatment. Additionally,
the treatment induced tumor regression, as assessed by caliper
measurements, and extensive apoptosis, as evidenced by
cleaved caspase-3 and TUNEL stainings. Similarly to other
phospholipid-binding imaging agents, [99mTc]duramycin may
not bind exclusively to apoptotic cells because necrotic tumor
areas also have numerous accessible PE. However, as the
COLO205 tumors lacked wide-spread regions of necrosis, as
observed macroscopically during sectioning and microscopi-
cally by H&E staining (Fig. 6b), the strong correlation between
the number of apoptotic cells and tracer tumor uptake in vivo
suggests that apoptotic tumor cells largely contributed to the
enhanced radiotracer uptake in treated tumors. Moreover,
in vitro [99mTc]duramycin uptake in irinotecan treated
COLO205 cells occurred in parallel to annexin-V binding
and effector caspase activation, indicating exposure of PS on
the cell membrane surface and caspase-akin selective uptake
into cells undergoing apoptosis, while membrane integrity is
still preserved, as evidenced by the exclusion of 7-amino-
actinomycin D (necrosis marker).
It is possible that binding to PE in the tumors may be
accompanied by nonspecific uptake. However, we found no
evidence of this possibility, since radiotracer uptake was not
increased in the tumors of vehicle-treated mice, suggesting a
specific treatment-induced uptake in the tumors. This
specificity of [99mTc]duramycin for cell death has previously
been reported, by Zhao and colleagues [16]. Using
inactivated duramycin they demonstrated a PE dependent
uptake of [99mTc]duramycin in infarcted tissue [16]. To
further evaluate non-specific binding of the tracer in treated
tumors a blocking study and imaging study with inactivated
duramycin will be performed. Furthermore, the use of
[99mTc]duramycin will also be validated using other types
of therapy (e.g., radiotherapy and targeted therapy) and other
preclinical tumor models with the aim of future SPECT
imaging in humans.
Conclusion
Our results show that [99mTc]duramycin has favorable
dosimetry estimates and specifically accumulates in apopto-
tic cells of tumors responding to chemotherapy, supporting
[99mTc]duramycin as a potential candidate for the assess-
ment of individualized responses to conventional therapy in
cancer patients.
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